HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sato, S Articles by Takehara, K Search for Related Content PubMed PubMed Citation Articles by Sato, S Articles by Takehara, K Related Collections Connective tissue disease

Antiphospholipid antibody in localised scleroderma

¹ Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
² Department of Regenerative Medicine, Research Institute, International Medical Centre of Japan, Tokyo, Japan

Correspondence to:
Correspondence to:
Dr S Sato, Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan;
s-sato{at}med.kanazawa-u.ac.jp

ABSTRACT
Objective: To investigate the prevalence and clinical correlation of antiphospholipid antibodies in localised scleroderma.

Methods: Antibodies against cardiolipin (aCL) or ß₂-glycoprotein I were examined by enzyme linked immunosorbent assay (ELISA) in 48 patients with localised scleroderma (18 patients with generalised morphoea, 20 with linear scleroderma, and 10 with morphoea). Twenty one of these patients were investigated for lupus anticoagulant (LAC) by screening and confirmatory coagulation tests.

Results: Patients with generalised morphoea, the severest form of localised scleroderma, had significantly raised levels of IgM or IgG aCL relative to normal controls (n=21) and patients with systemic sclerosis (n=20). The IgM isotype was predominant, with the frequency of IgM aCL (61%) higher than that of IgG aCL (28%). Levels of aCL were similar for patients with linear scleroderma or morphoea and normal controls. IgM aCL were associated with a greater number of lesions, especially plaque lesions, wider distribution of lesions, and the presence of immunological abnormalities including antinuclear antibodies, rheumatoid factor, IgM antihistone antibodies, IgG anti-single stranded DNA antibodies, and raised serum interleukin 6 levels in patients with localised scleroderma. LAC was detected in 5/7 (71%) patients with generalised morphoea. However, pulmonary embolism was seen in only one patient with generalised morphoea. None of patients with localised scleroderma exhibited anti-ß₂-glycoprotein I antibodies.

Conclusions: These results suggest that aCL and LAC are the major autoantibodies in patients with generalised morphoea.

Keywords: scleroderma; morphoea; antiphospholipid antibodies; anticardiolipin antibodies; lupus anticoagulant

Abbreviations: aCL, anticardiolipin antibodies; AHA, antihistone antibodies; ANA, antinuclear antibodies; aPL, antiphospholipid antibodies; ß₂GPI, ß₂-glycoprotein I; ELISA, enzyme linked immunosorbent assay; IL, interleukin; LAC, lupus anticoagulant; RF, rheumatoid factor; SSc, systemic sclerosis; ssDNA, single stranded DNA

This article has been cited by other articles:

				K. Takehara and S. Sato Localized scleroderma is an autoimmune disorder Rheumatology, March 1, 2005; 44(3): 274 - 279. [Abstract] [Full Text] [PDF]